People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Chemomab Therapeutics Ltd. | — | Biotechnology | Series C | $55.4M | $86.6M | 2024 |
Alan Charles Moses at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alan Charles Moses on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| MATTHEW FRANKEL | 1 | 2 |
| NIssim Darvish | 1 | 2 |
| Stephen P Squinto | 1 | 2 |
| Arnon Aharon | 1 | 2 |
| Adi Mor | 1 | 1 |
| Claude Charles Nicaise | 1 | 1 |
| Adi Mor George | 1 | 1 |
| Joel Michael Maryles | 1 | 1 |
| Nissim Charles Darvish | 1 | 1 |
| Sigal Fatal | 1 | 1 |
| Moses Charles Alan | 1 | 1 |
| Neil Harris Cohen | 1 | 1 |
| Jill Harris Quigley | 1 | 1 |
| Sigal Fattal | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.